Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1 22nd Annual Meeting of the American-Association-of-Endocrine-Surgeons Kivlen, M. H., Bartlett, D. L., Libutti, S. F., SKARULIS, M. C., Marx, S. J., Simonds, W. F., Weinstein, L. S., Jensen, R. T., McCart, J. A., Naik, A. M., Kranda, K. C., Brennan, M. F., NORTON, J. A., FRAKER, D. L., Alexander, H. R. MOSBY-ELSEVIER. 2001: 991–98


Patients with multiple endocrine neoplasia type 1 and hyperparathyroidism often undergo multiple operations because of inadequate initial surgery, presence of supernumerary and ectopic glands, regrowth of remnant glands, or autograft hyperfunction. Management of this patient population is complex.From January 1975 to December 2000 we performed 94 reoperative parathyroidectomies consisting of 79 neck reexplorations, 12 autograft removals, and 3 median sternotomies in 75 patients. Data were gathered by retrospective chart review and follow-up telephone interviews.Excluding autograft excision, reoperative surgery was successful (normocalcemia longer than 6 months) in 91%; autograft removal was successful in only 58%. With a median follow-up of 59 months, 64% of patients are currently free from hypercalcemia, and this outcome was not influenced by the total number of glands resected. The median time to recurrent hypercalcemia was 125 months. Thirty patients received an autograft after reoperation. The complication rate for all reoperations was 12%, including permanent recurrent laryngeal nerve injury in 2 patients (2.1%).Reoperative parathyroidectomy in patients with multiple endocrine neoplasia type 1 was safe and successful in the majority of patients; however, recurrent hyperparathyroidism is likely to develop in most individuals beyond 10 years of follow-up. The total number of glands accounted for after reoperation is not associated with successful outcome.

View details for DOI 10.1067/msy.2001.118379

View details for Web of Science ID 000173015300026

View details for PubMedID 11742328